However, it was quite recently announced (April 2022) that a phase 2 proof-of-concept trial would commence in order to evaluate the use of an MCHR1 antagonist known as RGH-076—under development by Gedeon Richter Plc.—as a treatment for hyperphagia/obesity in Prader-Willi syndrome. This evidence concerns the gene MCHR1 and obesity due to melanocortin 4 receptor deficiency.